On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

Axsome Therapeutics (AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy ...

Nevertheless, the existing data do support such a theory: the disease is strongly associated with a T-cell receptor α gene variant, and 95% of patients with narcolepsy with cataplexy carry the ...

AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and cortical dopamine modulator achieved the primary endpoint in the ENCORE trial (NCT05059223), reducing the frequency of cataplexy ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and ...

This novel drug is intended for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric narcolepsy patients aged six and older. The FDA’s decision fast-tracks the ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo ...